NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition

Core Insights - NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on developing innovative NK cell therapeutics, including autologous, allogeneic, and CAR-NK therapies [1][5] - The company will present its cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01, at the 5th International Cell & Gene Therapy China Summit & Exhibition, highlighting its potential in treating neurodegenerative diseases and solid tumors [1][2] Company Presentation Details - Dr. Paul Y. Song will present on May 23, 2024, discussing the challenges in manufacturing autologous NK cells at scale and how NKGen's next-gen CMC manufacturing process has successfully addressed these challenges [3] - The presentation will cover the results of SNK01 in combination with immune checkpoint inhibitors for advanced solid tumors and its use with Erbitux in resistant non-small cell lung cancer [3] Scientific Rationale and Data - The presentation will emphasize SNK01's ability to improve levels of amyloid beta, tau, and alpha-synuclein proteins, as well as other biomarkers associated with various neurodegenerative diseases, suggesting its potential for treatment and prevention in high-risk patients [4]